Recruiting NCT04766177
Role of Bumetanide in Treatment of Autism
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Bumetanide, Placebo.
- Who it may be relevant to
- Registry conditions: Autism. Basic parameters: 3 years — 12 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children
Overview
Role of bumetanide in Autism
Detailed description
Role of Bumetanide in Treatment of Autism spectrum disorder in children
Interventions
- Drug Bumetanide
bumetanide 0.5 mg twice daily - Drug Placebo
placebo tablets twice daily
Primary outcome measures
- Number of patients with improved CARS score [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- All patients with ASD diagnosed by CARS rating Scale⩾30.
- Age of patients range between (3-12) years.
Exclusion criteria
- Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Sherief Abd-Elsalam — Tanta
Identifiers
NCT: NCT04766177 · autism